IntelGenx Enters Animal Health Market by Signing Feasibility Agreement for VetaFilm™ Platform
January 09 2020 - 8:00AM
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”) a leader in
pharmaceutical films, today announced that it has entered into a
Feasibility Study Agreement (the “Agreement”) with an undisclosed
partner (the “Partner”) focused on bringing innovative animal
health products to the market.
Pursuant to the Agreement, IntelGenx will
conduct a feasibility study on an undisclosed molecule for buccal
absorption using IntelGenx’s proprietary VetaFilm™ platform. Based
on successful feasibility, IntelGenx will have exclusive rights to
further develop, manufacture and supply the developed product to
the Partner.
“This agreement marks our foray into the animal
health space,” said Dr. Horst G. Zerbe, CEO of IntelGenx. “Previous
studies have demonstrated that our proprietary VetaFilm™ drug
delivery platform offers a unique way of delivering drugs to
companion animals, and we believe that this delivery form will
become a standard for pets in the future. We are excited to
establish this important partnership with a leading animal health
industry player that shares our enthusiasm for the prospects of
oral thin film delivery in the animal health market.”
About IntelGenx
IntelGenx is a leading drug delivery company
focused on the development and manufacturing of pharmaceutical
films.
IntelGenx’s superior film technologies,
including VersaFilm®, VetaFilm™ and transdermal, allow for next
generation pharmaceutical products that address unmet medical
needs. IntelGenx’s innovative product pipeline offer significant
benefits to patients and physicians for many therapeutic
conditions.
IntelGenx's highly skilled team provides
comprehensive pharmaceuticals services to pharmaceutical partners,
including R&D, analytical method development, clinical
monitoring, IP and regulatory services. IntelGenx's
state-of-the-art manufacturing facility offers full service by
providing lab-scale to pilot- and commercial-scale production. For
more information, visit www.intelgenx.com.
Forward Looking Statements:
This document may contain forward-looking
information about IntelGenx' operating results and business
prospects that involve substantial risks and uncertainties.
Statements that are not purely historical are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and Section 27A of the Securities
Act of 1933, as amended. These statements include, but are not
limited to, statements about IntelGenx' plans, objectives,
expectations, strategies, intentions or other characterizations of
future events or circumstances and are generally identified by the
words "may," "expects," "anticipates," "intends," "plans,"
"believes," "seeks," "estimates," "could," "would," and similar
expressions. All forward looking statements are expressly qualified
in their entirety by this cautionary statement. Because these
forward-looking statements are subject to a number of risks and
uncertainties, IntelGenx' actual results could differ materially
from those expressed or implied by these forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, those discussed under
the heading "Risk Factors" in IntelGenx' annual report on Form
10-K, filed with the United States Securities and Exchange
Commission and available at www.sec.gov, and also filed with
Canadian securities regulatory authorities at www.sedar.com.
IntelGenx assumes no obligation to update any such forward-looking
statements.
Each of the TSX Venture Exchange and OTCQX has
neither approved nor disapproved the contents of this press
release. Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Source: IntelGenx Technologies Corp.
For IntelGenx:
Stephen KilmerInvestor Relations (514) 331-7440 ext
232stephen@intelgenx.com
Or
Andre Godin, CPA, CAPresident and CFOIntelGenx Corp.(514)
331-7440 ext 203andre@intelgenx.com
Intelgenx Technologies (TSXV:IGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intelgenx Technologies (TSXV:IGX)
Historical Stock Chart
From Apr 2023 to Apr 2024